CJC-1295 is a GHRH analogue that restores physiological growth hormone pulsatility. For women, declining GH after age 30 contributes to body composition changes, reduced skin collagen, and impaired sleep — CJC-1295 addresses all three through a single mechanism.
CJC-1295 binds and activates GHRH receptors on somatotroph cells in the anterior pituitary, stimulating GH synthesis and pulsatile release. Unlike exogenous GH, CJC-1295 preserves the natural GH pulse pattern — critical for maintaining GH receptor sensitivity and avoiding the side effects of continuous GH elevation.
GH stimulates hepatic IGF-1 production, which mediates many of GH's anabolic effects — lean mass accretion, fat mobilization, and collagen synthesis. In women, IGF-1 levels decline with age alongside GH; CJC-1295 restores both, supporting body recomposition and connective tissue quality.
GH is predominantly released during slow-wave (deep) sleep. CJC-1295 amplifies this nocturnal GH pulse, improving sleep quality and recovery. Women with poor sleep quality, night sweats, or perimenopause-related sleep disruption may particularly benefit from bedtime CJC-1295 dosing.
CJC-1295 is most effective when stacked with Ipamorelin and injected before bed to align with natural GH release patterns. Fast for 2 hours before injection for optimal GH pulse amplitude.
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Weeks 1–4 (Loading) | 100 mcg CJC + 100 mcg Ipamorelin | 3x weekly, before bed | Inject 30–60 min before sleep. Fast for 2h before injection for optimal GH pulse. |
| Weeks 5–12 (Active) | 100–200 mcg CJC + 100 mcg Ipamorelin | 3–5x weekly, before bed | Increase frequency based on goals. 5x/week for body recomposition, 3x/week for anti-aging. |
| Maintenance (Weeks 13+) | 100 mcg CJC + 100 mcg Ipamorelin | 2–3x weekly | Maintenance dosing. Monitor IGF-1 every 3 months. |
| CJC with DAC (alternative) | 1–2 mg CJC-DAC | Once weekly SubQ | Convenient once-weekly protocol. Less physiological than without-DAC stack. |
| Benefit | Evidence Level | Mechanism | Timeframe |
|---|---|---|---|
| GH pulse restoration | Strong (clinical) | GHRH receptor agonism | 2–4 weeks |
| Body recomposition | Moderate | IGF-1 upregulation, lipolysis | 8–16 weeks |
| Sleep quality | Moderate | Nocturnal GH pulse amplification | 2–4 weeks |
| Skin & collagen | Moderate (indirect) | IGF-1, collagen synthesis | 12–20 weeks |
| Bone density | Moderate (GH data) | IGF-1, osteoblast activity | 6–12 months |
≥99% purity, third-party COA verified. Use code HEALTH for 15% off.
Shop CJC-1295 at Purgo LabsCJC-1295 is a GHRH analogue that stimulates pulsatile growth hormone release. In women, it is researched for body recomposition (lean mass gain, fat loss), anti-aging (skin quality, collagen synthesis), improved sleep quality, and addressing age-related GH decline (somatopause). Women over 35 who experience declining GH pulses may particularly benefit from CJC-1295 protocols.
Research protocols for women typically use 100–200 mcg per injection, administered subcutaneously 2–3 times per week. CJC-1295 with DAC (Drug Affinity Complex) has a longer half-life and can be dosed once weekly at 1–2 mg. CJC-1295 without DAC is typically stacked with Ipamorelin (100 mcg each) and injected 2–3x weekly before bed to align with natural GH pulses.
CJC-1295 does not directly affect estrogen, progesterone, or other sex hormones. It stimulates GH release, which increases IGF-1 production. Elevated IGF-1 may modestly influence estrogen metabolism in some women, but this effect is not clinically significant at research doses. Women on hormone replacement therapy (HRT) should monitor IGF-1 levels when using CJC-1295.
Yes — GH pulse restoration is one of the primary anti-aging applications of CJC-1295 in women. GH declines approximately 14% per decade after age 30, contributing to reduced skin collagen, increased visceral fat, decreased lean mass, and impaired sleep quality. CJC-1295 restores physiological GH pulsatility without the supraphysiological peaks associated with exogenous GH, making it a more targeted anti-aging approach.
CJC-1295 has a favorable safety profile in research. The most common side effects are transient water retention (first 2–4 weeks), mild injection site reactions, and occasional flushing. At research doses, CJC-1295 does not cause the joint pain, carpal tunnel, or insulin resistance associated with supraphysiological exogenous GH. Women with active cancer, diabetes, or thyroid conditions should consult a healthcare provider before use.
CJC-1295 without DAC (also called Modified GRF 1-29) produces a more physiological GH pulse pattern when stacked with Ipamorelin — mimicking the natural GH release rhythm. CJC-1295 with DAC provides a sustained GH elevation for 7–14 days per injection, which is more convenient but less physiological. For anti-aging and sleep quality, the without-DAC + Ipamorelin stack is generally preferred for women due to its more natural pulse pattern.
Most women report improved sleep quality and recovery within 2–4 weeks. Body recomposition effects (lean mass, fat loss) typically become noticeable at 8–12 weeks. Skin quality improvements (collagen, elasticity) are often reported at 12–16 weeks. IGF-1 levels typically rise within 2–4 weeks and can be measured via blood test to confirm response.
Yes — the CJC-1295 + Ipamorelin stack is the most commonly used GH-stimulating combination in research. CJC-1295 provides the GHRH signal (stimulates GH synthesis and release), while Ipamorelin provides the GHRP signal (amplifies GH pulse amplitude) without significantly raising cortisol or prolactin. The combination produces synergistic GH release that is 2–3x greater than either peptide alone.
Medical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.